Decreased Serum NCAM Levels Associated with Cognitive Impairment in Vascular Dementia

Abstract

Objective. Neural cell adhesion molecule (NCAM), a glycoprotein widely distributed in the brain, has recently been shown to regulate neuroplasticity. However, the role of NCAM in vascular dementia (VaD) is still unclear. The purpose of this study is to determine whether NCAM is involved in the course of VaD. Methods. Continuous recruitment of VaD patients and control population to join this study. Doctors or nurses are responsible for collecting their clinical characteristics including age, gender, formal education, heart rate, supine systolic blood pressure, supine diastolic blood pressure, fasting glucose, high-density lipoprotein, and low-density lipoprotein. Each participant received the Montreal Cognitive Assessment (MoCA) scale after being enrolled in the group. At the same time, their peripheral blood was collected, and their serum NCAM levels were measured by enzyme-linked immunosorbent assay (ELISA). Results. 98 VaD patients and 83 age- and sex-matched controls were enrolled. There was no significant statistical difference between the VaD group and the control group in terms of the comparison of clinical characteristics ( $p>0.05$ ). The MoCA score of VaD patients was significantly lower than that of the controls ( $27.9\pm 1.4$ vs. $23.0\pm 2.1$ points, $p<0.001$ ). In addition, the circulating NCAM level of VaD patients was also significantly lower than that of controls ( $21.7\pm 3.8$ vs. $17.6\pm 4.2$  ng/mL, $p<0.001$ ). The circulating NCAM level of VaD patients was significantly positively correlated with MoCA score ( $r=0.285$ , $p=0.026$ ). After adjusting for clinical characteristics, circulating NCAM levels are still an independent pathogenic factor of VaD (regression $\text{coefficient}=0.223$ , $p=0.034$ ). Conclusions. VaD patients have low circulating NCAM levels, which can be used as a potential predictor of VaD.